The naturally occurring RNA-nucleopeptide H-Ala-Tyr[5'-pUUAAAAC-3']-NH 2 is prepared via a solid-phase phosphite triester approach using NSiOMB/O-TBDMS-protected nucleosides. Preliminary 1 H-NMR studies show that the peptidyl unit has a remarkable effect on the conformational behaviour of the RNA moiety in the nucleopeptide.
INTRODUCTION
In the process of gene expression nucleic acid-protein interactions constitute a very important and multifarious stage. Practically all these interactions are of a noncovalent binding character. In the late 1950's it was discovered 1 that many RNA's and DNA's may be covalently linked to specific proteins. Later on it was established that the covalent attachment of proteins to nucleic acids forms an important step in the viral genome replication 2 . For example, the genome RNA of the poliovirus, isolated from virions, contains a covalently linked virus specific protein 3 (designated VPg for 'Ural Protein Genome-Linked'). Chemical and enzymatic degradation studies 4 revealed the presence of a phosphate diester bond between the 5'-hydroxyl of an uridine residue of the viral RNA and the phenolic hydroxy group of a tyrosine residue in the VPg.
As part of our continuous efforts 5 in optimizing the synthesis of nucleopeptides, we recently reported that the protection of exocyclic amino functions in nucleobases (i.e. adenine, cytosine or guanine) with the 2-(fe/t-butyldiphenylsilyloxymethyl)benzoyl (SiOMB) group was a promising alternative, due to its smooth removal with fluoride ion under virtually neutral conditions, for the well-established N-acyl protecting group strategy. The successful application of the SiOMB together with the protection of 2'-hydroxy 1 function of ribonucleosides with tertbutyldimethylsilyl (TBDMS) group was nicely demonstrated 7 in a solid-phase synthesis of an RNA fragment.
In order to widen the scope of the SiOMB-TBDMS protecting group strategy, we report here that the same strategy can be adopted for a solid-phase synthesis of the RNA nucleopeptide fragment H-Ala-Tyr[5'-pUUAAAAC-3']-NH 2 (14) of the nucleoprotein from the poliovirus.
EXPERIMENTAL
Acetonitrile, dioxane, dichloromethane, pyridine and N,Ndiisopropylethylamine were dried by refluxing with calcium hydride (5 g/L), distilled and stored over molecular sieves (4A). Dioxane was redistilled over lithium aluminium hydride (5 g/L) before use. Af,Af-dimethylformamide was stirred with calcium hydride (5 g/L) and distilled under reduced pressure. Triethylammonium hydrogen carbonate buffer (2 M) was prepared by passing a stream of carbon dioxide through a cooled (0°C) solution of triethylamine in water until a neutral solution was obtained. (7V,N-Diisopropyl) 2-cyanoethyl chloro phosphoramidite (3) 8 , bis(N,N-diisopropyl) 2-cyanoethyl phosphoramidite (8) and AP-o-nitrophenylsulfenylalanine 15 dicyclohexylammonium salt were prepared according to published procedures. lH-Tetrazole was purchased from Pharmacia. 5'-O-4,4'-Dimethoxytrityl-2'-O-(rert-buryldimethylsilyl)uridinyl-3'-0-(N,N-diisopropyl) 2-cyanoethyl phosphoramidite (4, B=uridine) and tyrosine amide were purchased from Synorchem and Novabiochem, respectively. TLC analysis was performed on Schleicher and Schull Fertigfolien F1500 LS254 with solvents systems: A (dichloromethane/methanol, 37/3, v/v); B (dichloromethane/methanol, 19/1, v/v); C (ethyl acetate/triethylamine, 39/1, v/v). Short column chromatography was performed on Kieselgel 60, 230-400 mesh (Merck). 'H-NMR spectra were measured at 600 MHz, using a Bruker AM-600 spectrometer, equipped with an ASPECT-3000, operating in the Fourier transform mode. Chemical shifts are given in ppm (6) relative to TMS (CDC1 3 ) or DSS (D 2 O).
3T
P-NMR and 13 C-NMR spectra were measured at 80.7 MHz and 50.3 MHz, respectively, using a JEOL JNM-FX 200 spectrometer. Chemical shifts are given in ppm (5) relative to 85% H 3 PO 4 ( 3I P-NMR) as external standard. FPLC analysis was carried out on a Pharmacia LCC-500 liquid chromatograph using a MonoQ HR 5/5 column (anion-exchange) or a ProRPC HR 5/10 column (reversed-phase). Gradient elution was performed at 20°C by building up a gradient starting with buffer A (0.01 M sodium hydroxide (anionexchange); 0.1 M triethylammonium acetate in water pH 7 (reversed-phase) and applying buffer B (0.01 M sodium hydroxide and 1.2 M sodium chloride (anion-exchange); 0.1 M triethylammonium acetate in water/acetonitrile, 1/9, v/v, pH 7 (reversed-phase) at a flow rate of 2.0 mL/min (anion-exchange) and 0.75 mL/min (reversed-phase). Gel filtration was carried out * To whom correspondence should be addressed on a Hiload Sephacryl 75 HR 16/120 by elution with 0.15 M triethylammonium hydrogen carbonate buffer at a flow rate of 1.5 rnL/min. Solid-phase synthesis was performed on a Gene Assembler (Pharmacia). The synthesis was conducted on a 10 fimo\ scale using derivatized Monobeads (Pharmacia). Solvents were HPLC-grade and dried over molecular sieves (3A, Fluka) before use. All manipulations during and after deprotection of the nucleopeptide were performed under sterile conditions. Glassware was rinsed with sterile water and heated at 120°C for 16 h before use. Gloves were used when necessary. -•SiOMB ') were prepared according to SiOMB -.SiOMB-were prepared from compounds 1 by phosphitylation with reagent 3 according to published procedures 7 .
5-

5'-a4,4'-Dimethoxytrityl-3'-O-(teit-butyldimethylsilyl)-2'-Osuccinoyl-4-N-2-(terf-butyldiphenylsilyloxymethyl)benzoyl cytidine (5)
To a solution of 2 (B=C SiOMB ) (1.03 g, 1.0 mmol) in pyridine (5 mL) was added succinic anhydride (0.30 g, 3.0 mmol) and 4-dimethylaminopyridine (0.02 g, 0.20 mmol). After the reaction mixture has been stirred for 5 h at 50°C, the solvent was evaporated, the residue dissolved in dichloromethane (75 mL) and washed with water (2 X20 mL). The organic layer was dried over magnesium sulphate and concentrated in vacuo. The crude product was purified by silica gel column chromatography ( 
Functionalisation of the solid support
To a solution of the succinoyl derivative 5 (0.80 g, 0.70 mmol) in dioxane (10 mL) was added 1-hydroxybenzotriazole (0.14 g, 1.05 mmol) and /V.W-dicyclohexylcarbodiimide (0.22 g, 1.05 mmol). After 6 h at 20°C the precipitate was removed by filtration. The filtrate, N-methylimidazole (0.28 mL, 3.50 mmol) and diisopropylethylamine (0.64 mL, 3.50 mmol) were added to the solid support (1.00 g, Monobeads). After the reaction mixture was shaken for 70 h at 20 °C, the solvents were removed by fdtration and the support was thoroughly rinsed with dioxane (25 mL), dichloromethane (25 mL), methanol (25 mL) and diethyl ether (10 mL). The extent of loading (73 fimol/g) was determined according to a published procedure 9 . A^-o-nitrophenylsulfenylalanyltyrosine amide (7) A^-o-Nitrophenylsulfenylalanine dicyclohexylammonium salt (0.23 g, 5.5 mmol) was added to a mixture of ethyl acetate/water (100 ml, 1/1, v/v) at 0°C. Sulphuric acid (5.5 mL, 1 N) was added and the organic phase was separated, washed with an aqueous sodium chloride solution (2x25 mL, saturated) and dried over magnesium sulphate. The solvent was evaporated and the residue was redissolved in dimethylformamide (25 mL). The solution was cooled (-5°C), tyrosine amide (0.90 g, 5.0 mmol), 1-hydroxybenzotriazole (0.75 g, 5.5 mmol) and Af,N'-dicyclohexylcarbodiimide were added. The reaction mixture was stirred for 16 h at 20°C. The precipitate was removed by filtration and die filtrate was concentrated in vacuo. The oily residue was dissolved in ethyl acetate (100 mL) and washed with potassium dihydrogen phosphate buffer (2x25 mL, 1 M), water (25 mL), aqueous sodium hydrogen carbonate (2x25 mL, 1 M) and water (25 mL). The organic layer was dried over magnesium sulphate and concentrated to a small volume (30 mL). (iV'-o-nitrophenylsulfenylalanyltyrosine amide) (N,Ndiisopropyl) 2-cyanoethyl phosphoramidite (9) To a solution of dipeptide 7 (0.20 g, 0.5 mmol), which was dried by evaporation with acetonitrile, and lH-tetrazole (44 mg, 0.63 mmol) in dry acetonitrile (3 mL) was added 8 (1.25 mL, 0.5 M in CH 2 C1 2 ). After stirring for 10 min, the reaction mixture was diluted with dichloromethane (50 mL), washed with aqueous sodium hydrogen carbonate (20 mL, 0.5 M) and aqueous sodium chloride (20 mL, saturated). The organic phase was dried over magnesium sulphate and concentrated in vacuo in the presence of toluene (5 mL). The crude product was purified by silica gel column chromatography (10 g, hexane/ethyl acetate/ triethylamine, 20/79/1 to 0/99/1, v/v/v) to give 9 (0.27 g, 88% yield) as a yellow foam. R f 0.74 (system C); 3I P-NMR (CH 2 C1 2 ) 5 147.0. 
Deprotection and purification of nucleopeptide 11 -14
The solid support containing immobilized 11 was removed from the column and treated with dry ammonia methanol (10.0 mL, saturated) for 1 h at 20°C. The solid support was removed by filtration and rinsed with dichloromethane/methanol (3 X15 mL, 1/1, v/v). The filtrate, containing 12, was concentrated in vacuo and the residue was evaporated with tetrahydrofuran (3 mL). To a solution of compound 12 in tetrahydrofuran (1 mL) was added 2-mercaptopyridine (12 mg, 0.1 mmol). After 16 h at 20°C, the reaction mixture was concentrated and purified by gel filtration on an LH20 column (3x20 cm) suspended in dichloromethane/methanol (1/2, v/v). To a solution of 13 in tetrahydrofuran (0.5 mL) was added tetrabutylammonium fluoride (1.0 mL, 1.0 M in THF). After 16 h at 20°C, sterile water (20 mL) was added and the mixture was extracted with diethyl ether (2 x 10 mL). The aqueous phase was concentrated in vacuo and redissolved in triethylammonium hydrogen carbonate buffer (1.5 mL, 0.15 M, CH 3 OH/H 2 O, 1/9, v/v). The product was purified by gel filtration on a Sephacryl column suspended in the same buffer to give 14 (3.9 mg). The aqueous phase was lyophilized twice from deuterium oxide (2x0.5 mL, 99.9%) to give 14 as a white solid. The NMR sample was prepared by dissolving 14 (3.9 mg) in deuterium oxide (0.6 mL, 99.9%) and a sodium phosphate buffer (20 /iL, pD 6.9, 25 mM). 70 (m, 35H, H-2', H-3', H-4', H-5', H-5"), 5.43 (d, 1H, H-5, C(7) , J 56 7,5 Hz), 5.54 (bs, 1H, H-l', A (6) 85 (d, 1H, H-l', A(3), i vv 3.4 Hz), 7.51 (d, 1H, H-6, C(7)), 7.74 (d, 1H, H-6, U(2))' 7.77 (bs, 3H, H-8, A(6), H-2, A(3) and A (4) 
RESULTS AND DISCUSSION
The required incoming ribonucleoside synthons 4 (Scheme 1) are readily accesible by phosphitylation of the known 7 5'-O-DMT-2'-0-TBDMS-N-SiOMB protected nucleosides 1 with (N,N-diisopropyl) 2-cyanoethyl chloro phosphoramidite (3) 8 in the presence of /V,N-diisopropylethylamine.
The ribonucleoside derivative 2 (B=C SiOMB ), a side-product isolated in the early stage of the synthesis of 1 (B=C S|° ), was applied for the functionalisation of the solid support. Thus, treatment of 2 (B=C si0MB ) with succinic anhydride and 4-dimethylaminopyridine in pyridine at elevated temperature yielded the succinoyl derivative 5. Subsequent condensation of 5 with the amino groups on the resin (Monobeads, Pharmacia) could be effected with N,W-dicyclohexylcarbodiimide in the presence of 1-hydroxybenzotriazole. The latter condensation reaction afforded immobilized cytosine 6 loaded with 70 /*mol nucleoside/g support as gauged 9 from the spectroscopic determination of the 'trityl-color'.
The immobilized and partially protected heptamer 10 (5'-OH) was now assembled by stepwise elongation of immobilized cytosine 6 (Scheme 2) using an automated Gene Assembler (Pharmacia). One elongation cycle comprises (see Table 1 equivalents) displayed no profound effect on the coupling efficiency. On the other hand, prolonged coupling (i.e. 90 instead of 60 min) had a beneficial effect on the coupling efficiency (i.e. 98%). At this stage, the phenolic hydroxyl function of tyrosine in the dipeptide 7 was phosphitylated with bisCMN-diisopropyl) 2-cyanoethyl phosphordiamidite (8) 10 by the agency of \H-tetrazole to give, after silica gel column chromatography, the homogeneous phosphoramidite 9 in 88% yield. Subsequent \H-tetrazole-mediated coupling of 9 with the immobilized heptamer 10 (step 2 in Table 1 ) afforded, after oxidation (step 3) of the resulting phosphite triester, the fully protected and immobilized nucleopeptide 11.
The nucleopeptide 11 was completely deprotected by the following three-step procedure. Ammonolysis (1 h at 20°C) of 11 effected the release of 12 from the solid support (R ) groups of 13 with fluoride ion resulted in the isolation of fully deprotected 14. Purification by gel filtration afforded the RNA-nucleopeptide 14, the homogeneity and identity of which was firmly established by FPLC analysis and NMR spectroscopy. Thus, P-NMR spectroscopy revealed ( Figure 1 ) the presence of seven distinct resonances, one of which (i.e. resonance at -4.3 ppm) is characteristic for the presence of the phosphate diester between the phenolic hydroxyl group of tyrosine and the 5'-end of the RNA moiety. Further, highresolution NMR spectroscopy showed that the RNAnucleopeptide 14 was in accord with the proposed structure (see Figure 2A /B). Interestingly, additional conformational analysis of the RNA-nucleopeptide indicated that the uridines at the 5'-terminal of the RNA moiety adopted, in contrast with the same units in the native RNA fragment 15 7 , preferentially an S-type (C2 '-endo) n conformation (see Table 2 ). Moreover, n.O.e.'s were observed between the H5 protons of tyrosine and the individual 2' and 3' protons of the 5'-terminal uridine residue, denoting that the peptide moiety dramatically alters the conformation of the RNA in the nucleopeptide. More detailed studies dealing with the unexpected conformational behaviour of the nucleopeptide will be published elsewhere 14 .
The synthesis of the nucleopeptide fragment H-Ala-Tyr[5'-pUUAAAAC-3']-NH 2 presented in this paper indicates that a solid-phase approach, based on the N-SiOMB/O-TBDMS protecting group strategy, can be applied to assemble nucleopeptides containing RNA-(P-O-)tyrosine bonds. It has to be noted, however, that the efficiency of the key coupling step between the peptide derivative 9 and immobilised 10 (see Scheme 2) could not be determined due to the absence of a suitable reporter group in the incoming peptide moiety. At present we are studying in detail wether this shortcoming can be nullified by anchoring an appropriate tag on the incoming peptidyl unit.
